SERDs (estrogen receptor degraders): all 235 studies that test it

Page 2 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.CompletedNCT01602380Phase 3Results posted
• Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenCompletedNCT01300351Phase 3Results posted
• Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung CancerTerminatedNCT00932152Phase 2Results posted
• Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.CompletedNCT00921115Phase 2Results posted
• A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal WomenCompletedNCT00875420Phase 2Results posted
• Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerCompletedNCT00871858Phase 2Results posted
• Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor TherapyTerminatedNCT00722072Phase 2Results posted
• Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial CancerCompletedNCT00617188Phase 2Results posted
• Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung CancerTerminatedNCT00592007Phase 2Results posted
• Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast CancerCompletedNCT00570323Phase 2Results posted
• Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs AnastrozoleTerminatedNCT00543127Phase 3Results posted
• Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast CancerCompletedNCT00534417Phase 2Results posted
• Fulvestrant in Hormone Refractory Prostate CancerCompletedNCT00476645Phase 2Results posted
• Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast CancerCompletedNCT00423917Phase 2Results posted
• Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast CancerCompletedNCT00357110Phase 2Results posted
• Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.CompletedNCT00334295Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgCompletedNCT00313170Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgCompletedNCT00305448Phase 2Results posted
• Faslodex in McCune-Albright SyndromeCompletedNCT00278915Phase 2Results posted
• A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedNCT00274469Phase 2Results posted
• Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast CancerCompletedNCT00259090Phase 2Results posted
• Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyCompletedNCT00256698Phase 3Results posted
• Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsCompletedNCT00253422Phase 3Results posted
• Fulvestrant in Treating Patients With Recurrent Prostate CancerTerminatedNCT00217464Phase 2Results posted
• Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00201864Phase 2Results posted
• A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)TerminatedNCT00183963Phase 2Results posted
• Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast CancerTerminatedNCT00138125Phase 2Results posted
• Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Active, not recruitingNCT00099437Phase 3Results posted
• S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast CancerCompletedNCT00075764Phase 3Results posted
• Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast CancerCompletedNCT00057941Phase 2Results posted
• Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial CancerStatus unknownNCT00006903Phase 2Results posted
• A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy AdultsCompletedNCT06911788Phase 1
• A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy AdultsCompletedNCT06645938Phase 1
• A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsCompletedNCT06547164Phase 1
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceActive, not recruitingNCT06492616Phase 3
• A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy AdultsCompletedNCT06347861Phase 1
• A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine VepdegestrantCompletedNCT06275841Phase 1
• A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called MidazolamCompletedNCT06256510Phase 1
• A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionCompletedNCT06126575Phase 1
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)TerminatedNCT06125522Phase 1/2
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2
• Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic StudyCompletedNCT06074757Phase 1
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Phase 3
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingNCT06016738Phase 3
• A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy ParticipantsCompletedNCT06005688Phase 1
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingNCT05952557Phase 3
• A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy AdultsCompletedNCT05930925Phase 1
• Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive, not recruitingNCT05909397Phase 3
• A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompletedNCT05896566Phase 2
• Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsCompletedNCT05790304Phase 1
• A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaCompletedNCT05732428Phase 1
• A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingNCT05708235Phase 2
• A Study of Giredestrant in Participants With Grade 1 Endometrial CancerCompletedNCT05634499Phase 2
• ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyActive, not recruitingNCT05596409Phase 2
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)TerminatedNCT05573555Phase 1/2
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingNCT05563220Phase 1/2
• A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleCompletedNCT05551897Phase 1
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingNCT05548127Phase 1/2
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingNCT05514054Phase 3
• A Study of LY3484356 in Chinese Participants With Advanced Breast CancerActive, not recruitingNCT05509790Phase 1
• ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast CancerCompletedNCT05501769Phase 1
• Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast CancerActive, not recruitingNCT05463601Phase 2
• Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersCompletedNCT05438303Phase 1
• SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)Active, not recruitingNCT05392608Phase 2
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2
• A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingNCT05306340Phase 3
• A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingNCT05296798Phase 3
• A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsActive, not recruitingNCT05266105Phase 1
• A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingNCT05154487Phase 2
• Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingNCT04961996Phase 3
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• Fulvestrant + Neratinib In Breast CancerWithdrawnNCT04901299Phase 2
• AZD9833 China PK StudyCompletedNCT04818632Phase 1
• Elacestrant in Preoperative Setting, a Window of Opportunity StudyCompletedNCT04797728Early Phase 1
• Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerTerminatedNCT04791384Phase 1/2
• The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast CancerStatus unknownNCT04753177Phase 2/3
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingNCT04711252Phase 3
• DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingNCT04567420Phase 2
• A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833CompletedNCT04546347Phase 1
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingNCT04546009Phase 3
• A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerCompletedNCT04541433Phase 1
• A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1
• Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2
• FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia StudyCompletedNCT03926936Phase 2
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
• HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• Fulvestrant in Metastatic Breast CancerStatus unknownNCT03591549Phase 4
• A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerStatus unknownNCT03560856Phase 2
• Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaActive, not recruitingNCT03531645Phase 2
• Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsActive, not recruitingNCT03393845Phase 2
• A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT03332797Phase 1
• Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM AdministrationCompletedNCT03324061Phase 1
• HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceTerminatedNCT03322215Phase 2
• The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerStatus unknownNCT03202862Phase 2
• Metformin and Simvastatin in Addition to FulvestrantStatus unknownNCT03192293Phase 2
• The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCompletedNCT03079011Phase 3

← SERDs (estrogen receptor degraders) overview